We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current DXNHF market cap is 0. The company's latest EPS is EUR and P/E is N/A.
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Revenue | 50.41M | 58.89M | 188.46M | 183.69M | 152.17M |
| Operating Income | 1.63M | 3.41M | 81.21M | 70.12M | 30.87M |
| Net Income | -2.77M | 3.15M | 73.48M | 60.54M | 24.94M |
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Assets | 69.9M | 81.01M | 172.3M | 209.87M | 330.73M |
| Total Liabilities | 41.67M | 45.76M | 65.19M | 49.32M | 158.08M |
| Total Equity | 28.23M | 35.25M | 107.11M | 160.55M | 172.65M |
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Operating | -523k | 4.99M | 54.93M | 65.92M | 43.07M |
| Investing | -1.55M | -4.39M | -3.99M | -5.47M | -141.76M |
| Financing | 1.27M | -4.01M | 7.05M | -23.76M | 82.31M |
| Market Cap | 0 |
| Price to Earnings Ratio | N/A |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 0 |
| Price to Book Ratio | 0 |
| Dividend Yield | - |
| Shares Outstanding | 11.34M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 0 (0%) |
| Company Name | Diaxonhit (CE) |
| Address |
7, avenue de scandinavie , za de courtaboeuf les ulis, essonne 91953 |
| Website | https://www.eurobio-scientific.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
